To provide additional evidence for the specificity of ASMase overexpression in radiosensitizing tumor neo-angiogenic vasculature, we repeated the entire body of work using a second promoter, the murine VEGFR2 promoter. The gene discussed is SMPD1; the disease is neoplasm.